Last updated: 11/04/2018 12:30:30
A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Phase II, multi-centre, open-label, randomised study to evaluate the safety, tolerability and pharmacokinetics of oral sitamaquine compared with amphotericin B in the treatment of visceral leishmaniasis caused by L. donovani in endemic areas.
Trial description: Sitamaquine is an 8-aminoquinoline which is being developed as an oral treatment for visceral leishmaniasis (VL). Pre-clinical and subsequent clinical investigations have demonstrated oral efficacy against Leishmania donovani. The purposes of this study are to characterise the pharmacokinetic profile of sitamaquine, administered orally, and to determine if the pharmacokinetic profile is affected by administration with food. The study is also designed to further characterise the safety and tolerability of sitamaquine compared with amphotericin B, particularly in reference to renal, hepatic and cardiac adverse events, prior to initiation of phase III studies. Finally the study will investigate the efficacy of a 21 day treatment course. Previous studies have used 28 days dosing, but parasitological evidence from one study suggests that shorter courses may be effective.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Area under the concentration-time curve over the dosing interval AUC(0-tau) for sitamaquine
Timeframe: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose
Maximum plasma concentration (Cmax) for sitamaquine
Timeframe: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose.
Time to maximum observed plasma concentration (tmax) for sitamaquine
Timeframe: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose.
Accumulation ratio for sitamaquine
Timeframe: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose
Secondary outcomes:
Number of participants with adverse events(AEs) and serious adverse events(SAEs)
Timeframe: Up to 180 days
Number of participants with abnormal 12-lead Electrocardiogram (ECG) values
Timeframe: Up to Day 49 for Sitamaquine and Day 58 for Amphotericin B
Number of participants with abnormal echocardiography results
Timeframe: Day 22 and 49 (sitamaquine only) and Day 31 and 58 (amphotericin B only) and withdrawal
Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) up to Day 180
Timeframe: Baseline (Day 1 pre-dose) up to Day 180
Change from Baseline in heart rate
Timeframe: Baseline (Day 1 pre-dose) up to Day 180
Change from Baseline in body temperature
Timeframe: Baseline (Day 1 pre-dose) up to Day 180
Change from Baseline in body weight
Timeframe: Baseline (Day 1 pre-dose) up to Day 49 for Sitamaquine and Day 58 for Amphotericin B
Number of participants with abnormal hematology values up to Day 180
Timeframe: Up to Day 180
Number of participants with abnormal clinical chemistry values up to Day 180
Timeframe: Up to Day 180
Number of participants with Initial parasitological cure (28 days)
Timeframe: Up to 28 days
Number of participants with Final clinical cure (6 months)
Timeframe: Up to 180 days
Terminal elimination half-life (t1/2) for sitamaquine
Timeframe: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose
Interventions:
Enrollment:
61
Primary completion date:
2007-14-09
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Sundar S, Sinha PK, Dixon SA, Buckley R, Miller AK, Mohamed K, Al-Banna M. Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India. Am J Trop Med Hyg. 2011 Jun;84(6):892-900. doi: 10.4269/ajtmh.2011.10-0409.
Sundar S, Sinha PK, Dixon SA, Buckley R, Miller AK, Mohamed K, Al-Banna M. Pharmacokinetics of Oral Sitamaquine Taken with or without Food and Safety and Efficacy for Treatment of Visceral Leishmaniais: A Randomized Study in Bihar, India. Am J Trop Med Hyg. 2011 Jun;84(6):892-900
Medical condition
Leishmaniasis, Visceral
Product
sitamaquine
Collaborators
Not applicable
Study date(s)
August 2006 to September 2007
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
16 - 50 years
Accepts healthy volunteers
No
- Clinical diagnosis of visceral leishmaniasis; symptoms and signs compatible with VL and diagnosis confirmed by visualisation of amastigotes in splenic aspirate or bone marrow.
- Written informed consent or witnessed oral consent.
- Past history of renal disease or impaired renal function at screening.
- History of any significant hepatic or biliary disease, or the following abnormal laboratory values at screening; hepatic dysfunction (AST or ALT 2.5 times upper limit of normal).
Inclusion and exclusion criteria
Inclusion criteria:
- Clinical diagnosis of visceral leishmaniasis; symptoms and signs compatible with VL and diagnosis confirmed by visualisation of amastigotes in splenic aspirate or bone marrow.
- Written informed consent or witnessed oral consent.
- Willing to comply with the study visits and procedures.
- For female subjects, a negative urine pregnancy test at screening and before dosing and the subject agrees to use an established method of birth control (including abstinence).
Exclusion criteria:
- Past history of renal disease or impaired renal function at screening.
- History of any significant hepatic or biliary disease, or the following abnormal laboratory values at screening; hepatic dysfunction (AST or ALT 2.5 times upper limit of normal).
- Subjects with the following abnormal laboratory values; haemoglobin 6.5 g/dl, neutrophils <750/ mm3, platelets <50,000 / mm3, any clinically relevant abnormality identified on screening examination or clinical laboratories which would preclude the subject’s safe participation in the study.
- History of cardiac disease, arrhythmias, conduction abnormalities or any clinically relevant abnormality identified on 12-lead ECG at screening. Subjects suffering from a concomitant infection, blood disorder or any other serious underlying disease which would preclude evaluation of the subject’s response to the study medication. Methaemoglobin levels >5% at screening. G6PD deficiency.
- Positive HIV antibody, hepatitis B surface antigen or hepatitis C antibody at screening.
- Pregnant or nursing women; women of childbearing potential who are unwilling or unable to use an appropriate form of contraception, from prior to study medication administration until 2 weeks following the last dose of investigational product.
- Any contraindication to splenic aspirate (or bone marrow aspirate), including but not limited to PT prolonged >3 seconds longer than control or platelets <50,000 / mm3.
- Subjects with a known hypersensitivity reaction to 8-aminoquinolines (e.g. primaquine) or any of the investigational product excipients.
- Treatment with an established antileishmanial chemotherapeutic agent within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
- Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2007-14-09
Actual study completion date
2007-14-09
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website